Progenity, Inc.

40 articles about Progenity, Inc.

• Progenity Announces Successful Transfer of Liquid Biopsy Technologies

  5/5/2022

  Progenity, Inc. announced it has completed the divesture of a collection of novel, discovery-stage biochemical and bioinformatics technologies, including single-molecule detection, which are designed to enable next-generation rapid, low-cost assessment of biomolecules via liquid biopsy.

• Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.

  5/3/2022

  Progenity, Inc. (Nasdaq: PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets.

• 

  Allogene, Progenity, Adaptive Phage Tout New Top Executives

  4/29/2022

  Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

• Progenity Appoints Paul Shabram to Lead Technical Operations of the Company’s Ingestible Drug/Device Platforms

  4/25/2022

  Progenity, Inc., a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, announced the appointment of Paul Shabram, MBA, as Senior Vice President, Technical Operations.

• Progenity to Become Biora Therapeutics as it Completes Transformation

  4/12/2022

  Progenity, Inc. announced that it will change its name to Biora Therapeutics, Inc. during the second quarter of 2022, to better reflect the company’s focus on developing its pipeline for targeted and systemic oral delivery of biotherapeutics.

• Progenity Announces Two Poster Presentations at Controlled Release Society 2022

  4/6/2022

  Progenity, Inc. today announced the acceptance of two abstracts presenting preclinical data on its systemic therapeutics delivery system for presentation at the Controlled Release Society (CRS) 2022 Annual Meeting.

• Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

  3/28/2022

  Progenity, Inc., an innovative biotechnology company, provided a corporate update and reported financial results for the fourth quarter and full-year ended December 31, 2021.

• Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update

  3/16/2022

  Progenity, Inc., a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, announced that it will report financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 28, 2022 after the close of financial markets.

• Progenity Progresses its Drug Delivery System Clinical Device Performance Studies

  3/10/2022

  Progenity, Inc., an innovative biotechnology company, announced progress with its clinical device performance study plan, evaluating the device function and safety of its Drug Delivery System capsule.

• Progenity Announces Acceptance of Three Abstracts at Digestive Disease Week 2022

  2/28/2022

  Progenity, Inc., a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, announced the acceptance of three abstracts on the treatment of IBD and microbiome sampling for presentation at Digestive Disease Week®.

• Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO’22

  2/22/2022

  Progenity, Inc. today shared two poster presentations that were presented during the 17th Congress of the European Crohn’s and Colitis Organisation (ECCO) on February 18, 2022.

• Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology

  2/16/2022

  Progenity, Inc., a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, shared an oral presentation that was delivered by Dr. Bram Verstockt during the 34th edition of the Belgian Week of Gastroenterology on February 9, 2022.

• Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional Patent

  1/25/2022

  Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the award of another new patent related to its single-molecule detection assay platform under development.

• Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology

  1/11/2022

  Progenity, Inc. today announced that patient data on indicators of efficacy in the treatment of gastrointestinal disorders has been accepted for oral presentation during the 34th edition of the Belgian Week of Gastroenterology, February 9-11, 2022.

• Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22

  1/5/2022

  Progenity, Inc. announced that two presentations with patient data on indicators of efficacy in the treatment of gastrointestinal disorders have been accepted by the 17th Congress of the European Crohn’s and Colitis Organisation, February 16-19, 2022, the world’s largest forum for IBD specialists.

• Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference

  1/3/2022

  Progenity, Inc. today announced that the company will participate in a pre-recorded presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The presentation will be available on the conference website beginning at 7 a.m. Eastern / 4 a.m. Pacific on January 10, 2022.

• Progenity Completes Exit from Laboratory Business with Sale of Affiliate LabTransaction Adds Cash to Balance Sheet and Further Reduces Operating Expenses

  12/20/2021

  Progenity, Inc., a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, announced it has successfully closed the business divestiture of its affiliate Avero Diagnostics through an asset sale to Northwest Pathology.

• Progenity Announces New Patent for Single-Molecule Detection Technology

  12/2/2021

  Progenity, Inc. today announced a new patent related to its single-molecule detection platform under development.

• Progenity Strengthens its Liquidity Position

  11/23/2021

  Company received more than $44 million in warrant exercises since August 2021.

• Progenity to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/15/2021

  Progenity, Inc., an innovative biotechnology company, announced that the company will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will be available on the conference website beginning at 10 a.m. Eastern / 7 a.m. Pacific on November 22, 2021.